New Castanospermine Glycoside Analogues Inhibit Breast Cancer Cell Proliferation and Induce Apoptosis without Affecting Normal Cells

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Allan, Ghada ^a   Ouadid Ahidouch, Halima ^a   Sanchez Fernandez, Elena M ^b   Risquez Cuadro, Rocío ^b   Fernandez, José M Garcia ^c   Ortiz Mellet, Carmen ^b   Ahidouch, Ahmed ^a,d  

^a Université Picardie Jules Vernes   (France)

^b UNIVERSITY OF SEVILLE   (Spain)

^c INSTITUTO DE INVESTIGACIONES QUÍMICAS   (Spain)

^d IBN ZOHR UNIVERSITY   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

CASTANOSPERMINE DERIVATIVE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; GLYCOSIDE; LIPOCORTIN 5; PROTEIN BAX; PROTEIN BCL 2; PSEUDO C OCTYL GLYCOSIDE 2 OXA 3 OXOCASTANOSPERMINE; PSEUDO S OCTYL GLYCOSIDE 2 OXA 3 OXOCASTANOSPERMINE; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL CULTURE; CELL SPECIFICITY; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLIZINES;

EID: 84885029143     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076411     Document Type: Article

References (72)

1. Malumbres M, Barbacid M, (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nature reviews Cancer 9: 153-166.
2. Malumbres M, Ortega S, Barbacid M, (2000) Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors. Biological chemistry 381: 827-838.
3. Rashidian J, Iyirhiaro GO, Park DS, (2007) Cell cycle machinery and stroke. Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease 1772: 484-493.
4. Schwartz GK, Shah MA, (2005) Targeting the cell cycle: a new approach to cancer therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23: 9408-9421.
5. Williams GH, Stoeber K, (2012) The cell cycle and cancer. The Journal of pathology 226: 352-364.
6. Alle KM, Henshall SM, Field AS, Sutherland RL, (1998) Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clinical cancer research: an official journal of the American Association for Cancer Research 4: 847-854.
7. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, et al. (1994) Cyclin E, a potential prognostic marker for breast cancer. Cancer Research 54: 380-385.
8. Zukerberg LR, Yang WI, Gadd M, Thor AD, Koerner FC, et al. (1995) Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 8: 560-567.
9. Wang L, Shao ZM, (2006) Cyclin e expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer investigation 24: 581-587.
10. Rudolph P, Kuhling H, Alm P, Ferno M, Baldetorp B, et al. (2003) Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. International journal of cancer Journal international du cancer 105: 674-680.
11. Russo A, Terrasi M, Agnese V, Santini D, Bazan V, (2006) Apoptosis: a relevant tool for anticancer therapy. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 17Suppl 7: vii115-123.
12. Lehen'kyi V, Shapovalov G, Skryma R, Prevarskaya N, (2011) Ion channnels and transporters in cancer. 5. Ion channels in control of cancer and cell apoptosis. American journal of physiology Cell physiology 301: C1281-1289.
13. van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, et al. (1996) Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. British journal of cancer 74: 78-85.
14. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, et al. (2010) BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. British journal of cancer 103: 668-675.
15. Callagy GM, Webber MJ, Pharoah PD, Caldas C, (2008) Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC cancer 8: 153.
16. Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, et al. (2008) Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast cancer research: BCR 10: R35.
17. Lederkremer GZ, (2009) Glycoprotein folding, quality control and ER-associated degradation. Current opinion in structural biology 19: 515-523.
18. Aebi M, Bernasconi R, Clerc S, Molinari M, (2010) N-glycan structures: recognition and processing in the ER. Trends in biochemical sciences 35: 74-82.
19. Ruiz-Canada C, Kelleher DJ, Gilmore R, (2009) Cotranslational and posttranslational N-glycosylation of polypeptides by distinct mammalian OST isoforms. Cell 136: 272-283.
20. Helenius A, (1994) How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum. Molecular biology of the cell 5: 253-265.
21. Trombetta ES, Helenius A, (1998) Lectins as chaperones in glycoprotein folding. Current opinion in structural biology 8: 587-592.
22. Klausner RD, Sitia R, (1990) Protein degradation in the endoplasmic reticulum. Cell 62: 611-614.
23. Brodsky JL, McCracken AA, (1997) ER-associated and proteasomemediated protein degradation: how two topologically restricted events came together. Trends in cell biology 7: 151-156.
24. Sommer T, Wolf DH, (1997) Endoplasmic reticulum degradation: reverse protein flow of no return. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 11: 1227-1233.
25. Shamu CE, Cox JS, Walter P, (1994) The unfolded-protein-response pathway in yeast. Trends in cell biology 4: 56-60.
26. Brostrom CO, Brostrom MA, (1998) Regulation of translational initiation during cellular responses to stress. Progress in nucleic acid research and molecular biology 58: 79-125.
27. Melero JA, Fincham V, (1978) Enhancement of the synthesis of specific cellular polypeptides in a temperature-sensitive Chinese hamster cell line (K12) defective for entry into S phase. Journal of cellular physiology 95: 295-306.
28. Carlberg M, Larsson O, (1993) Role of N-linked glycosylation in cell-cycle progression and initiation of DNA synthesis in tumor-transformed human fibroblasts. Anticancer research 13: 167-171.
29. Potapenko IO, Haakensen VD, Luders T, Helland A, Bukholm I, et al. (2010) Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Molecular oncology 4: 98-118.
30. Hadwiger A, Niemann H, Kabisch A, Bauer H, Tamura T, (1986) Appropriate glycosylation of the fms gene product is a prerequisite for its transforming potency. The EMBO journal 5: 689-694.
31. Humphries MJ, Matsumoto K, White SL, Olden K, (1986) Inhibition of experimental metastasis by castanospermine in mice: blockage of two distinct stages of tumor colonization by oligosaccharide processing inhibitors. Cancer Research 46: 5215-5222.
32. Ostrander GK, Scribner NK, Rohrschneider LR, (1988) Inhibition of v-fms-induced tumor growth in nude mice by castanospermine. Cancer Research 48: 1091-1094.
33. Pili R, Chang J, Partis RA, Mueller RA, Chrest FJ, et al. (1995) The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Research 55: 2920-2926.
34. Wrodnigg TM, Steiner AJ, Ueberbacher BJ, (2008) Natural and synthetic iminosugars as carbohydrate processing enzyme inhibitors for cancer therapy. Anti-cancer agents in medicinal chemistry 8: 77-85.
35. Aguilar-Moncayo M, Gloster TM, Turkenburg JP, Garcia-Moreno MI, Ortiz Mellet C, et al. (2009) Glycosidase inhibition by ring-modified castanospermine analogues: tackling enzyme selectivity by inhibitor tailoring. Organic & biomolecular chemistry 7: 2738-2747.
36. Blanco Jimenez J, Vargas Nunez JA, Yebra Bango M, Cristobal Varela C, Durantez Martinez A, (1997) [Brown-Sequard syndrome secondary to dissecting aortic aneurysm]. Revista clinica espanola 197: 299-301.
37. Aguilar-Moncayo M, Takai T, Higaki K, Mena-Barragan T, Hirano Y, et al. (2012) Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis. Chemical Communications 48: 6514-6516.
38. Alfonso P, Andreu V, Pino-Angeles A, Moya-Garcia AA, Garcia-Moreno MI, et al. (2013) Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher disease. Chembiochem: a European journal of chemical biology 14: 943-949.
39. Takai T, Higaki K, Aguilar-Moncayo M, Mena-Barragan T, Hirano Y, et al. (2013) A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Molecular therapy: the journal of the American Society of Gene Therapy 21: 526-532.
40. Tiscornia G, Vivas EL, Matalonga L, Berniakovich I, Barragan Monasterio M, et al. (2013) Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Human molecular genetics 22: 633-645.
41. Sánchez-Fernández EM, Rîsquez-Cuadro R, Chasseraud M, Ahidouch A, Ortiz Mellet C, et al. (2010) Synthesis of N-, S-, and C-glycoside castanospermine analogues with selective neutral [small alpha]-glucosidase inhibitory activity as antitumour agents. Chemical Communications 46: 5328-5330.
42. Faouzi M, Kischel P, Hague F, Ahidouch A, Benzerdjeb N, et al. (2013) ORAI3 silencing alters cell proliferation and cell cycle progression via c-myc pathway in breast cancer cells. Biochimica et biophysica acta 1833: 752-760.
43. Ekholm SV, Reed SI, (2000) Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Current opinion in cell biology 12: 676-684.
44. Jackman M, Lindon C, Nigg EA, Pines J, (2003) Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nature cell biology 5: 143-148.
45. Gavet O, Pines J, (2010) Activation of cyclin B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis. The Journal of cell biology 189: 247-259.
46. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN, (1993) Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Seminars in cancer biology 4: 327-332.
47. Oltvai ZN, Milliman CL, Korsmeyer SJ, (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619.
48. Nguyen M, Folkman J, Bischoff J, (1992) 1-Deoxymannojirimycin inhibits capillary tube formation in vitro. Analysis of N-linked oligosaccharides in bovine capillary endothelial cells. The Journal of biological chemistry 267: 26157-26165.
49. Horne G, Wilson FX, Tinsley J, Williams DH, Storer R, (2011) Iminosugars past, present and future: medicines for tomorrow. Drug discovery today 16: 107-118.
50. Skelding KA, Rostas JA, Verrills NM, (2011) Controlling the cell cycle: the role of calcium/calmodulin-stimulated protein kinases I and II. Cell Cycle 10: 631-639.
51. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG, (2004) Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145: 5439-5447.
52. Sherr CJ, Roberts JM, (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes & development 13: 1501-1512.
53. Parodi AJ, (2000) Role of N-oligosaccharide endoplasmic reticulum processing reactions in glycoprotein folding and degradation. The Biochemical journal 348 Pt 1: 1-13.
54. Bravo R, Parra V, Gatica D, Rodriguez AE, Torrealba N, et al. (2013) Endoplasmic reticulum and the unfolded protein response: dynamics and metabolic integration. International review of cell and molecular biology 301: 215-290.
55. Kaufman RJ, (1999) Molecular chaperones and the heat shock response. Sponsored by Cold Spring Harbor Laboratory, 6-10 May 1998. Biochimica et biophysica acta 1423: R13-27.
56. Brewer JW, Hendershot LM, Sherr CJ, Diehl JA, (1999) Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression. Proceedings of the National Academy of Sciences of the United States of America 96: 8505-8510.
57. Brewer JW, Diehl JA, (2000) PERK mediates cell-cycle exit during the mammalian unfolded protein response. Proceedings of the National Academy of Sciences of the United States of America 97: 12625-12630.
58. Zhao Y, Zhou Y, Murphy PV, (2010) Biological study of the angiogenesis inhibitor N-(8-(3-ethynylphenoxy)octyl-1-deoxynojirimycin. Chemical biology & drug design 75: 570-577.
59. Zhao Y, Zhou Y, O'Boyle KM, Murphy PV, (2008) Hybrids of 1-deoxynojirimycin and aryl-1,2,3-triazoles and biological studies related to angiogenesis. Bioorganic & medicinal chemistry 16: 6333-6337.
60. Hsu JL, Chiang PC, Guh JH, (2009) Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78. Naunyn-Schmiedeberg's archives of pharmacology 380: 373-382.
61. Chiang PC, Hsu JL, Yeh TC, Pan SL, Guh JH, (2008) Elucidation of susceptible factors to endoplasmic reticulum stress-mediated anticancer activity in human hepatocellular carcinoma. Naunyn-Schmiedeberg's archives of pharmacology 377: 167-177.
62. Han C, Jin L, Mei Y, Wu M, (2013) Endoplasmic reticulum stress inhibits cell cycle progression via induction of p27 in melanoma cells. Cellular signalling 25: 144-149.
63. Bobrovnikova-Marjon E, Diehl JA, (2007) Coping with stress: ATF6alpha takes the stage. Developmental cell 13: 322-324.
64. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A, (2009) Targeting the endoplasmic reticulum-stress response as an anticancer strategy. European journal of pharmacology 625: 234-246.
65. Koumenis C, (2006) ER stress, hypoxia tolerance and tumor progression. Current molecular medicine 6: 55-69.
66. Tsai YC, Weissman AM, (2010) The Unfolded Protein Response, Degradation from Endoplasmic Reticulum and Cancer. Genes & cancer 1: 764-778.
67. Kang MH, Reynolds CP, (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 1126-1132.
68. Veronese S, Mauri FA, Caffo O, Scaioli M, Aldovini D, et al. (1998) Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. International journal of cancer Journal international du cancer 79: 13-18.
69. Sun JY, Yang H, Miao S, Li JP, Wang SW, et al. (2009) Suppressive effects of swainsonine on C6 glioma cell in vitro and in vivo. Phytomedicine: international journal of phytotherapy and phytopharmacology 16: 1070-1074.
70. Sun JY, Zhu MZ, Wang SW, Miao S, Xie YH, et al. (2007) Inhibition of the growth of human gastric carcinoma in vivo and in vitro by swainsonine. Phytomedicine: international journal of phytotherapy and phytopharmacology 14: 353-359.
71. Li Z, Huang Y, Dong F, Li W, Ding L, et al. (2012) Swainsonine promotes apoptosis in human oesophageal squamous cell carcinoma cells in vitro and in vivo through activation of mitochondrial pathway. Journal of biosciences 37: 1005-1016.
72. Abbas T, Dutta A, (2009) p21 in cancer: intricate networks and multiple activities. Nature reviews Cancer 9: 400-414.